cancers Review Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe? Agnete Witness Praest Jensen 1, Ana Micaela Carnaz Simões 1, Per thor Straten 1,2,* and Gitte Holmen Olofsson 1,* 1 National Center for Cancer Immune Therapy (DK-CCIT), Department of Oncology, University Hospital, DK-2730 Herlev, Denmark;
[email protected] (A.W.P.J.);
[email protected] (A.M.C.S.) 2 Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark * Correspondence:
[email protected] (P.t.S.);
[email protected] (G.H.O.); Tel.: +45-3868-2675 (P.t.S.); +45-3868-6418 (G.H.O.) Simple Summary: Exercise is associated with many aspects of a healthy lifestyle. Among these, exercise leads to the secretion of adrenaline and noradrenaline, which mobilize cells of the immune system, a process which is suggested to possess therapeutic value in cancer therapy, alone or in combination with immunotherapy. Strikingly, administration of β-blockers—which block the effect of adrenaline/noradrenaline—are also suggested to be useful in cancer therapy alone or in combination with immunotherapy. Herein we discuss the question of whether exercise and the administration of β-blockers could potentially be useful in cancer therapy. Abstract: The incidence of cancer is increasing worldwide, which is to a large extent related to the population’s increasing lifespan. However, lifestyle changes in the Western world are causative as well. Exercise is intrinsically associated with what one could call a “healthy life”, and physical activity Citation: Jensen, A.W.P.; Carnaz is associated with a lower risk of various types of cancer.